Glucosio Bioindustria L.I.M.

Glucosio Bioindustria L.I.M. is a parenteral carbohydrate solution that contains glucose monohydrate as its sole active ingredient. It is supplied in an injectable form for intramuscular or intravenous administration and complies with European Union pharmaceutical standards. The product delivers a readily available source of glucose to support cellular energy metabolism in clinical settings where rapid carbohydrate supplementation is needed, and it is provided in sterile containers for controlled use.

Glucosio Bioindustria L.I.M. is used as an immediate source of carbohydrate in various medical situations that require rapid energy provision or maintenance of blood glucose levels.

- Intravenous or intramuscular supplementation of glucose in patients undergoing surgery or anesthesia. - Management of hypoglycemia when oral intake is not feasible. - Provision of caloric support in critically ill or trauma patients. - Support of metabolic needs during parenteral nutrition regimens. - Replacement of fluid and electrolyte losses associated with glucose depletion.

The safety profile of Glucosio Bioindustria L.I.M. reflects the expected pharmacologic actions of glucose administered intravenously or intramuscularly.

Common: - Transient hyperglycemia - Local irritation at the injection site - Mild nausea - Headache - Temporary increase in serum osmolality

Serious: - Severe hyperglycemia leading to osmotic diuresis - Allergic or anaphylactic reaction - Hyperosmolar hyperglycemic state - Metabolic acidosis in predisposed patients - Venous thrombosis related to infusion

When using Glucosio Bioindustria L.I.M., clinicians should consider several precautionary measures to ensure safe administration.

- Verify patient’s blood glucose level before and after infusion. - Adjust dose in patients with renal or hepatic impairment. - Use caution in individuals with diabetes mellitus or insulin resistance. - Monitor electrolyte balance, especially sodium and potassium, during large-volume administration. - Avoid rapid infusion rates to reduce risk of circulatory overload. - Ensure aseptic technique to prevent infection at the injection site. - Review concurrent carbohydrate intake to prevent excess caloric load.

Glucose solutions can interact with other medications or clinical conditions; awareness of these interactions helps optimize therapy.

Avoid: - Concurrent administration of high-dose insulin without glucose monitoring. - Use with hyperosmolar agents that may exacerbate fluid shifts. - Co-administration with drugs that cause hypoglycemia (e.g., sulfonylureas) without adjustment.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Diuretics that alter electrolyte status. - Corticosteroids that increase glucose production. - Catecholamines or glucagon that raise blood glucose levels. - Total parenteral nutrition formulations containing additional carbohydrates.